中国P站

Microbiome; Gut-brain axis; Mental health; Metabolic diseases; Cancer immunotherapy; Autoimmune diseases; Neurodegenerative diseases; Cardiovascular disease; Pharmaco-microbiomics; Skin microbiome; Oral microbiome; Infant development

Introduction

The human microbiome, a diverse community of microorganisms inhabiting various body sites, increasingly recognized as central to health and disease. It influences a wide array of physiological functions, spanning immune regulation, metabolic processes, and neurological pathways. Research into these complex microbial ecosystems is unveiling potential therapeutic targets and personalized health strategies. The gut microbiome, particularly, is a major focus, demonstrating profound systemic effects.One pivotal study explored the intricate relationship between the human gut microbiome and mental health outcomes, emphasizing bidirectional communication along the gut-brain axis. It revealed how psychological stress, environmental exposures, and host biology collectively influence microbial composition, which then impacts neurotransmitter production, immune responses, and overall brain function. The authors suggested an integrated approach to mental health interventions, potentially incorporating microbiome modulation[1].

Another significant review explored the critical role of the gut microbiome in modulating responses to cancer immunotherapy. Specific microbial compositions and their metabolites can either enhance or impair the efficacy of treatments such as immune checkpoint inhibitors. This work bridged basic science to clinical translation, discussing microbiome modulation strategies, including fecal microbiota transplantation and dietary interventions, to improve patient outcomes and overcome therapeutic resistance[2].

A specific publication delved into the critical role of the infant gut microbiome in shaping lifelong health and developmental trajectories. Factors like birth mode, feeding practices, and antibiotic exposure influence early microbial colonization, affecting immune system maturation, metabolic programming, and neurodevelopment. This research highlighted the potential for early-life interventions to establish a beneficial microbiome, aiming to prevent chronic diseases later in life[3].

A comprehensive review summarized the causal links between the gut microbiome and metabolic diseases, including obesity and Type 2 Diabetes. It dissected mechanisms where microbial dysbiosis contributes to energy harvest, insulin resistance, and systemic inflammation. Emerging therapeutic strategies like prebiotics, probiotics, and fecal microbiota transplantation were explored for modulating the gut microbiome to manage these prevalent disorders[4].

Exploring the dynamic nature of the skin microbiome and its profound impact on dermatological health was also crucial. The delicate balance of skin microbial communities influences barrier function, immune responses, and susceptibility to conditions like eczema, acne, and psoriasis. This investigation pointed to therapeutic opportunities through targeted modulation of skin microbiota, including bacteriotherapy and pre/probiotic applications, for improved skin health[5].

An updated review further highlighted profound connections between the oral microbiome and various systemic diseases, moving beyond traditional links to periodontal disease. It detailed how oral dysbiosis contributes to cardiovascular diseases, diabetes, and adverse pregnancy outcomes via systemic inflammation and microbial translocation. The work stressed the importance of a healthy oral microbiota for overall systemic well-being and disease prevention[6].

Significant contributions from the gut microbiome were explored in a separate review regarding the pathogenesis and progression of autoimmune diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis. Microbial dysbiosis can disrupt immune tolerance, leading to chronic inflammation and autoimmunity through molecular mimicry, metabolite production, and gut barrier integrity. This research highlighted the therapeutic potential of targeting the microbiome to restore immune balance[7].

The emerging field of pharmacomicrobiomics, illustrating how the human gut microbiome significantly influences drug metabolism and efficacy, also received attention. It described mechanisms by which microbial enzymes activate, inactivate, or modify therapeutic compounds, impacting drug bioavailability and patient responses. This article emphasized considering individual microbiome profiles for personalized medicine to optimize drug dosing and minimize adverse effects[8].

Emerging evidence linking the gut microbiome to the pathogenesis of neurodegenerative diseases, including Alzheimer's and Parkinson's, was discussed in another work. The 'gut-brain axis' in neurodegeneration shows how microbial dysbiosis can induce neuroinflammation, oxidative stress, and protein misfolding in the brain. This review suggested that modulating the gut microbiome could offer novel therapeutic strategies for preventing or slowing these debilitating conditions[9].

Finally, expanding evidence for a strong link was reviewed in an update demonstrating a clear connection between the gut microbiome and the development of cardiovascular diseases, such as atherosclerosis, heart failure, and hypertension. It highlighted the role of specific microbial metabolites, like trimethylamine N-oxide (TMAO), in disease progression. This work suggested that manipulating the gut microbiota through diet or targeted interventions is a promising strategy for preventing and treating cardiovascular conditions[10].

Description

The gut microbiome is now recognized as a pivotal regulator of numerous systemic health aspects. Its intricate involvement with mental health is evident through the gut-brain axis, where factors like psychological stress and environmental exposures profoundly influence microbial composition. This, in turn, impacts neurotransmitter production, immune responses, and overall brain function, highlighting microbiome modulation as a potential therapeutic path for mental health interventions [1]. Similarly, the gut microbiome harbors causal links to metabolic diseases such as obesity and Type 2 Diabetes. Microbial dysbiosis contributes to crucial mechanisms like altered energy harvest, insulin resistance, and systemic inflammation. Therapeutic strategies involving prebiotics, probiotics, and fecal microbiota transplantation are actively explored to manage these prevalent conditions [4]. The 'gut-brain axis' also emerges in the context of neurodegenerative diseases, including Alzheimer's and Parkinson's. Here, microbial dysbiosis can induce neuroinflammation, oxidative stress, and protein misfolding in the brain, suggesting microbiome modulation as a novel strategy to slow disease progression [9]. Furthermore, the gut microbiome significantly contributes to the pathogenesis and progression of autoimmune diseases like rheumatoid arthritis, lupus, and multiple sclerosis. Dysbiosis can disrupt immune tolerance, leading to chronic inflammation and autoimmunity through molecular mimicry and metabolite production, underscoring its therapeutic potential to restore immune balance [7]. Finally, expanding evidence demonstrates a strong link between the gut microbiome and cardiovascular diseases, including atherosclerosis, heart failure, and hypertension, with specific microbial metabolites such as trimethylamine N-oxide (TMAO) implicated in disease progression. This suggests microbiota manipulation could be a promising prevention and treatment strategy [10].

The influence of microbial communities extends significantly beyond the gut, playing critical roles in other major bodily sites. The skin microbiome, for instance, is a dynamic ecosystem with profound impacts on dermatological health and disease. The delicate balance of these microbial communities directly affects barrier function, immune responses, and susceptibility to conditions like eczema, acne, and psoriasis. Current research reveals exciting therapeutic opportunities through targeted modulation of the skin microbiota, employing bacteriotherapy and pre/probiotic applications to enhance skin health [5]. Concurrently, the oral microbiome has been identified for its profound connections to various systemic diseases, moving past its traditional association with periodontal issues. Oral dysbiosis contributes to serious conditions such as cardiovascular diseases, diabetes, and even adverse pregnancy outcomes, primarily through systemic inflammation and microbial translocation. Maintaining a healthy oral microbiota is increasingly recognized as a key factor in overall systemic well-being and disease prevention [6].

Early-life microbial colonization is another area of immense importance. The infant gut microbiome critically shapes lifelong health and developmental trajectories. Factors like birth mode, feeding practices, and early antibiotic exposure significantly influence this initial microbial establishment, impacting immune system maturation, metabolic programming, and even neurodevelopment. There is substantial potential for early-life interventions aimed at establishing a beneficial microbiome, thereby preventing chronic diseases later in life [3]. Additionally, the human microbiome, especially in the gut, plays a significant role in pharmacomicrobiomics, influencing drug metabolism and efficacy. This emerging field describes how microbial enzymes can activate, inactivate, or modify therapeutic compounds, directly impacting drug bioavailability and patient responses. Considering individual microbiome profiles is crucial for advancing personalized medicine, as it allows for optimized drug dosing and minimized adverse effects, ultimately improving therapeutic outcomes [8].

The collective body of research paints a compelling picture of the microbiome as a central regulator of health, suggesting a holistic view of human physiology. This paradigm shift emphasizes the interconnectedness of microbial ecosystems with almost every major organ system and disease state. The recurring theme across these studies is the immense therapeutic potential offered by strategically modulating these microbial communities. Whether through dietary interventions, prebiotics, probiotics, or more advanced techniques like fecal microbiota transplantation, manipulating the microbiome offers novel strategies to restore immune balance, optimize metabolic function, and combat disease progression. These insights advocate for an integrated approach to health interventions, where microbiome modulation becomes a fundamental component in personalized medicine for prevention and treatment across a spectrum of human conditions.

Conclusion

The human microbiome is pivotal to health, exerting influence across diverse physiological systems. Research highlights the gut microbiome's intricate links to mental health via the gut-brain axis, where microbial composition impacts neurotransmitter production and brain function. It also profoundly affects metabolic diseases, contributing to insulin resistance and systemic inflammation. The gut microbiota's role extends to immune function, influencing autoimmune conditions and modulating responses to cancer immunotherapies, where specific microbial profiles can enhance treatment efficacy. Beyond the gut, the skin microbiome is crucial for dermatological health and barrier function, while the oral microbiome connects to systemic diseases like cardiovascular issues and diabetes. Early-life microbial colonization is vital for immune and neurodevelopment, shaping lifelong health trajectories. Furthermore, the gut microbiome significantly influences drug metabolism, impacting therapeutic efficacy. A strong link between gut microbiota and cardiovascular diseases, involving metabolites like TMAO, is also evident. This broad understanding underscores microbiome modulation as a promising therapeutic strategy for a wide array of health challenges, advocating for an integrated approach to overall well-being.

References

• Laura CK, Katharina SW, Paul DO (2023) .Clin Psychol Sci 11:21677026231174984.

, ,

• Jennifer LW, Emily MD, Diya BS (2022) .Cell Host Microbe 30:289-305.

, ,

• Meghan BA, Andrea MH, Robert MGvdH (2021) .Gastroenterology 160:187-200.e2.

, ,

• Peer B, Jeroen R, Oluf P (2020) .Cell Metab 31:181-197.

, ,

• Richard LG, Stephan RW, J. AM (2023) .Nat Rev Microbiol 21:679-695.

, ,

• Yu KL, Sung HK, Min JP (2024) .J Clin Periodontol 51:e13962.

, ,

• Qiao L, Wenjuan Z, Wei M (2022) .Front Immunol 13:880993.

, ,

• Rania SA, Mona MG, Mariam ME (2021) .Pharmacol Res Perspect 9:e00756.

, ,

• Sang-Hwa L, Chang HL, Young MK (2023) .Int J Mol Sci 24:8232.

, ,

• W. HWT, Stanley LH, Josef N (2019) .Circ Res 125:1369-1382.

, ,